This is a working overview of 免疫组织, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
The first pathway (see the reaction illustrated below) involves the deamination of histamine by the enzyme diamine oxidase to form imidazole acetaldehyde. In the second pathway, histamine is metabolized into Nτ-methylhistamine (also known as 1-methylhistamine), which also has some biological activity, albeit much weaker than that of histamine. Still, NMT, being a product in a reaction catalyzed by HNMT, may inhibit expression of HNMT in a negative feedback loop. This reaction is Nτ-methylation of histamine by the histamine N-methyltransferase (HNMT) enzyme. The Nτ-methylhistamine, unless excreted by the kindney, is subsequently oxidized into Nτ-methylimidazoleacetic acid (Nτ-MIAA) by the enzyme monoamine oxidase (MAO). This two-step process reduces the activity of histamine in the body and is important for quick deactivation of histamine in the brain. The third pathway is found exclusively in enterobacteria and has not been identified in mammals. This pathway involves the acetylation of histamine by an acetylase to form 4-(-acetylaminoethyl)imidazole. DAO catalyzes the oxidative deamination of polyamines, such as histamine and putrescine, to produce aminoaldehydes, hydrogen peroxide, and ammonia.
=== Machine learning and statistics === In machine learning, one-hot encoding is a frequently used method to deal with categorical data. Because many machine learning models need their input variables to be numeric, categorical variables need to be transformed in the pre-processing part.
Firstly, as revealed by computational chemistry studies, the unpaired electron is stabilized through delocalization by the aromatic ring of tyrosine and the cross-linked cysteine sulfur, with the oxygen atom of Tyr272 possessing high unpaired electron density. Some experimental evidence also suggests that axial Tyr495 is also involved in unpaired electron delocalization. Secondly, the indole ring of a tryptophan (Trp290) lies above and parallel to Tyrosine-Cysteine, behaving like a shield protecting the radical from the external solvent environment. Supporting evidence comes from that mutation of this tryptophan residue leads to a lower stability of the active form of galactose oxidase. Additionally, the outer sphere of the active site consists of many aromatic residues that give the active site a hydrophobic character. There are also extensive hydrogen bonding networks surround the active site.
== Further reading == Buzuev, Vladimir; Gorodnov, Vladimir (1987). What Is Marxism–Leninism?. Moscow: Progress Publishers. "Marxism–Leninism". Encyclopedia of Marxism. Marxists Internet Archive. Retrieved 31 December 2020. Kuusinen, Otto Will (1963). Fundamentals of Marxism–Leninism. Translated by Dutt, Clemens (2nd rev. ed.). Moscow: Foreign Languages Publishing House. OCLC 1091006. OL 5975949M. Kuusinen, Otto Will (2022). Fundamentals of Marxism–Leninism. Translated by Dutt, Clemens. United States: Marx Engels Lenin Press. ISBN 979-8-8114-4663-6. Sheptulin, Alexander. Marxist-Leninist Philosophy. Moscow: Progress Publishers. OL 2170371W. Stalin, Joseph (1924). "The Foundations of Leninism". Works. Vol. 6. Moscow: Foreign Languages Publishing House. pp. 71–196. Spirkin, Alexander (1990). Fundamentals of Philosophy. Translated by Syrovatkin, Sergei. Moscow: Progress Publishers. ISBN 978-5-0100-2582-3.
Sources: en.wikipedia.org
=== Two-step mechanism – autocatalysis model === In 1997, Finke and Watzky proposed a new kinetic model for the nucleation and growth of nanoparticles. This 2-step model suggested that constant slow nucleation (occurring far from supersaturation) is followed by autocatalytic growth where dispersity of nanoparticles is largely determined. This F-W (Finke-Watzky) 2-step model provides a firmer mechanistic basis for the design of nanoparticles with a focus on size, shape, and dispersity control. The model was later expanded to a 3-step and two 4-step models between 2004 and 2008. Here, an additional step was included to account for small particle aggregation, where two smaller particles could aggregate to form a larger particle. Next, a fourth step (another autocatalytic step) was added to account for a small particle agglomerating with a larger particle. Finally in 2014, an alternative fourth step was considered that accounted for a atomistic surface growth on a large particle.
== Mutations == Y184F – Abolishes phosphorylation. Y304F – Decreases activity by two-thirds and alters conformation. S364A – Strong decrease of phosphorylation by PRKACA (the catalytic subunit of protein kinase A).
In 2023, lawmakers approved Pritzker's Smart Start Illinois program, providing expanded public funding for preschool programs and for child care providers. The program increased the number of preschool seats available to 80% of all working families, with 11,000 additional preschool seats added as of January 2025.
== Prevention == No prevention mechanism exists for Sjögren's disease (SjD) because of its complexity as an autoimmune disorder. However, lifestyle changes can reduce the risk factors related to developing SjD or reduce the severity of the condition for patients who have already been diagnosed. Diet is strongly associated with the inflammation seen in many autoimmune-related diseases, including SjD. An experimental study concluded that SjD patients often show high gluten sensitivity that directly relates to inflammation. Moderate exercise is also helpful in SjD patients, mainly reducing the effect of lung inflammation.
=== Sclerodactyly === Though it is the most easily recognizable manifestation, it is not prominent in all patients. Thickening generally only involves the skin of the fingers distal to the metacarpophalangeal joints in CREST. Early in the course of the disease, the skin may appear edematous and inflamed. Eventually, dermal fibroblasts overproduce extracellular matrix leading to increased tissue collagen deposition in the skin. Collagen cross-linking then causes a progressive skin tightening. Digital ischemic ulcers commonly form on the distal fingers in 30–50% of patients.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.